Opdualag™
Understanding Opdualag™
Opdualag™ is a combination immunotherapy consisting of two agents:
- Nivolumab (Opdivo®): A PD-1 inhibitor that helps immune cells recognize and attack cancer cells.
- Relatlimab: A LAG-3 inhibitor that further enhances T-cell activation, strengthening the immune system’s response against cancer.
How Opdualag™ Works:
- Blocks PD-1 and LAG-3, two immune checkpoint pathways that cancer cells use to evade detection.
- Boosts T-cell activation, allowing the immune system to attack cancer cells more effectively.
- Enhances the immune response, providing a dual-targeted approach to cancer treatment.
FDA Approval:
- Opdualag™: Approved on March 18, 2022
For more information, please visit the Opdualag™ patient website and speak with your healthcare provider to determine if Opdualag™ is the right treatment option for you.
Referral Form: |
WHAT IT TREATS: |
MANUFACTURER: Bristol Myers Squibb (BMS) |
CLASS: Checkpoint Inhibitor Immunotherapy
PD-1 inhibitor (nivolumab)
LAG-3 inhibitor (relatlimab) |
|
PRESCRIBED BY:
|
|
HOW ADMINISTERED: IV Infusion |
|
FREQUENCY: Every four weeks |
Length of infusion: 30 mins |
FOR MORE INFORMATION: |
Related drugs
